Winslow Capital Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $295K | Sell |
4,708
-4,695
| -50% | -$376K | ﹤0.01% | 58 |
|
|
2025
Q4 | $897K | Sell |
9,403
-535
| -5% | -$52.5K | ﹤0.01% | 53 |
|
|
2025
Q3 | $970K | Sell |
9,938
-722
| -7% | -$74.8K | ﹤0.01% | 53 |
|
|
2025
Q2 | $1.14M | Sell |
10,660
-2,647,680
| -100% | -$268M | ﹤0.01% | 54 |
|
|
2025
Q1 | $268M | Sell |
2,658,340
-475,732
| -15% | -$47.9M | 1.07% | 35 |
|
|
2024
Q4 | $280M | Sell |
3,134,072
-286,624
| -8% | -$25.2M | 0.99% | 36 |
|
|
2024
Q3 | $287M | Sell |
3,420,696
-1,213,490
| -26% | -$95.7M | 1.03% | 38 |
|
|
2024
Q2 | $357M | Sell |
4,634,186
-212,053
| -4% | -$15.5M | 1.29% | 30 |
|
|
2024
Q1 | $332M | Sell |
4,846,239
-187,779
| -4% | -$12.1M | 1.25% | 30 |
|
|
2023
Q4 | $291M | Sell |
5,034,018
-1,095,555
| -18% | -$58.5M | 1.21% | 34 |
|
|
2023
Q3 | $324M | Buy |
6,129,573
+1,730,133
| +39% | +$90.7M | 1.54% | 27 |
|
|
2023
Q2 | $238M | Buy |
+4,399,440
| New | +$230M | 1.07% | 34 |
|
|
2020
Q4 | – | Sell |
-5,458,870
| Closed | -$209M | – | 64 |
|
|
2020
Q3 | $209M | Buy |
5,458,870
+1,353,537
| +33% | +$52.2M | 0.93% | 41 |
|
|
2020
Q2 | $144M | Buy |
+4,105,333
| New | +$148M | 0.7% | 45 |
|
|
2020
Q1 | – | Sell |
-4,757,016
| Closed | -$215M | – | 55 |
|
|
2019
Q4 | $215M | Buy |
+4,757,016
| New | +$199M | 1.12% | 36 |
|
|
2019
Q1 | – | Sell |
-482
| Closed | -$17K | – | 73 |
|
|
2018
Q4 | $17K | Sell |
482
-45
| -9% | -$1.63K | ﹤0.01% | 74 |
|
|
2018
Q3 | $20K | Sell |
527
-34
| -6% | -$1.19K | ﹤0.01% | 76 |
|
|
2018
Q2 | $18K | Sell |
561
-429
| -43% | -$12.9K | ﹤0.01% | 71 |
|
|
2018
Q1 | $27K | Sell |
990
-5,207
| -84% | -$142K | ﹤0.01% | 66 |
|
|
2017
Q4 | $154K | Sell |
6,197
-11,855,199
| -100% | -$327M | ﹤0.01% | 64 |
|
|
2017
Q3 | $346M | Buy |
11,861,396
+648,613
| +6% | +$17.9M | 1.86% | 18 |
|
|
2017
Q2 | $311M | Buy |
11,212,783
+2,011,640
| +22% | +$53.4M | 1.66% | 22 |
|
|
2017
Q1 | $229M | Sell |
9,201,143
-3,136,583
| -25% | -$76.3M | 1.09% | 47 |
|
|
2016
Q4 | $267M | Buy |
12,337,726
+2,025,932
| +20% | +$44.2M | 1.23% | 30 |
|
|
2016
Q3 | $245M | Sell |
10,311,794
-867,886
| -8% | -$20.7M | 1.02% | 50 |
|
|
2016
Q2 | $261M | Sell |
11,179,680
-10,896,250
| -49% | -$236M | 1.07% | 47 |
|
|
2016
Q1 | $415M | Buy |
22,075,930
+819,364
| +4% | +$14.4M | 1.63% | 23 |
|
|
2015
Q4 | $392M | Buy |
21,256,566
+1,641,002
| +8% | +$29.4M | 1.4% | 31 |
|
|
2015
Q3 | $322M | Buy |
19,615,564
+2,152,198
| +12% | +$36.8M | 1.17% | 39 |
|
|
2015
Q2 | $309M | Buy |
+17,463,366
| New | +$312M | 1.03% | 48 |
|
Other funds holding BSX
VCM
VPM
Winslow Capital Management's BSX Position: Q1 2026 in Review
Winslow Capital Management reduced its Boston Scientific (BSX) stake by 50% in Q1 2026, selling an estimated $376K and leaving 4,708 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #58.
Winslow Capital Management first reported a position in BSX in Q2 2015 and has held it in 30 quarters since. The position peaked at $415M in Q1 2016. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Winslow Capital Management held 4,708 shares of Boston Scientific worth $295K as of Q1 2026.
- Winslow Capital Management sold 4,695 Boston Scientific shares in Q1 2026, an estimated $376K.
- Boston Scientific made up ﹤0.01% of Winslow Capital Management's portfolio in Q1 2026, its #58 holding.
- Winslow Capital Management first reported a position in Boston Scientific in Q2 2015 and has held it in 30 quarters since.
- Winslow Capital Management's Boston Scientific position peaked at $415M in Q1 2016.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Winslow Capital Management's 13F filing for Q1 2026, filed 14 May 2026.